We Help Companies Find New Sales Opportunities
Powderject's new US parent Chiron is to relocate 12 senior managers from Uxbridge to the Powderject office in Oxford.
Powderject is planning to invest £85m at its vaccine production plant in Liverpool over the next five years, with the creation of an unspecified number of jobs.
Powderject, the vaccine maker, is to be acquired by Chiron of the US for more than £540m.
Powderject is to set up a direct sales force to sell its flu vaccine, with the creation of 25 jobs.
Powderject has announced plans to invest £13m at its Evans Vaccines plant in Speke, in order to increase production of flu vaccines.
Powderject Pharmaceuticals has acquired SBL Vaccin, the Swedish vaccines company, for £35m, and is now looking to sell the rights to its needleless syringe.
Powderject is to lease part of its recently-acquired vaccines plant in Speke to Aviron, which will enable the US company to set up a plant to manufacture flu vaccines.
Powderject Pharmaceuticals has agreed to acquire the UK vaccines business of Celltech for £55m.